Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Ivuxolimab (Primary) ; Axitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 28 Aug 2024 Planned End Date changed from 19 Jul 2025 to 19 Jul 2026.
- 28 Aug 2024 Planned primary completion date changed from 19 Jul 2024 to 19 Jul 2025.
- 09 Aug 2023 Planned End Date changed from 19 Jul 2024 to 19 Jul 2025.